The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
Open accessAbstract
Playing Hide and Seek: Targeted cancer therapies have shown promising results in patients, but few of these drugs provide long-term benefits because tumor cells rapidly develop drug resistance. Nathanson et al. (p. 72 , published online 5 December) show that glioblastoma cells can become resistant to erlotinib, an epidermal growth factor receptor (EGFR)–targeted drug, by eliminating extrachromosomal copies of the mutant EGFR gene. After a period of drug withdrawal, the mutant EGFR gene reappears on extrachromosomal DNA and the tumor cells become resensitized. The discovery that cancer cells can evade drug therapy by this “hide and seek” mechanism may help to optimize the dosing schedule of erlotinib in glioblastoma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Cancerous stem cells can arise from pediatric brain tumors
Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., Bronner-Fraser, M., & Kornblum, H. I. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036535100 · Cited by 1,817
Self-citationStochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Self-citationChaffer, C. L., Marjanovic, N. D., Lee, T., Bell, G., Kleer, C. G., Reinhardt, F., D’Alessio, A. C., Young, R. A., & Weinberg, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.06.005 · Cited by 876
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 661
Self-citationInda, M.-D.-M., Bonavia, R., Mukasa, A., Narita, Y., Sah, D. W. Y., Vandenberg, S., Brennan, C., Johns, T. G., Bachoo, R., Hadwiger, P., et al. (2010) · Genes & Development · doi:10.1101/gad.1890510 · Cited by 543
Self-citationHeimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., & Aldape, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1737 · Cited by 516
Circumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503
Heterogeneity Maintenance in Glioblastoma: A Social Network
Bonavia, R., Inda, M.-D.-M., Cavenee, W. K., & Furnari, F. B. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0153 · Cited by 439
Self-citationHumphrey, P. A., Wong, A. J., Vogelstein, B., Zalutsky, M. R., Fuller, G. N., Archer, G. E., Friedman, H. S., Kwatra, M. M., Bigner, S. H., & Bigner, D. D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4207 · Cited by 382
Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., Oldrini, B., Chheda, M. G., Yannuzzi, N., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0284 · Cited by 343
Self-citationCharacterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.
Bigner, S. H., Humphrey, P. A., Wong, A. J., Vogelstein, B., Mark, J., Friedman, H. S., & Bigner, D. D. (1990) · PubMed · Cited by 331
Giannini, C., Sarkaria, J. N., Saito, A., Uhm, J. H., Galanis, E., Carlson, B. L., Schroeder, M. A., & James, C. D. (2005) · Neuro-Oncology · doi:10.1215/s1152851704000821 · Cited by 326
Self-citationGene Amplification and Drug Resistance in Cultured Murine Cells
Schimke, R. T., Kaufman, R. J., Alt, F. W., & Kellems, R. F. (1978) · Science · doi:10.1126/science.715457 · Cited by 314
Aldape, K. D., Ballman, K., Furth, A., Buckner, J. C., Giannini, C., Burger, P. C., Scheithauer, B. W., Jenkins, R. B., & James, C. D. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.7.700 · Cited by 278
Self-citationAmplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
Ercan, D., Zejnullahu, K., Yonesaka, K., Xiao, Y., Capelletti, M., Rogers, A., Lifshits, E., Brown, A., Lee, C., Christensen, J. G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.526 · Cited by 228
Sarkaria, J. N., Yang, L., Grogan, P. T., Kitange, G. J., Carlson, B. L., Schroeder, M. A., Galanis, E., Giannini, C., Wu, W., Dinca, E. B., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0691 · Cited by 200
Self-citationVogt, N., Lefèvre, S.-H., Apiou, F., Dutrillaux, A.-M., Cör, A., Leuraud, P., Poupon, M.-F., Dutrillaux, B., Debatisse, M., & Malfoy, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402979101 · Cited by 170
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
Glickman, M. S., & Sawyers, C. L. (2012) · Cell · doi:10.1016/j.cell.2012.02.015 · Cited by 168
Fitz, C. D. V., Giacomini, C. P., Vogel, H. S., Jensen, K. C., Florio, T., Merlo, A., Pollack, J. R., & Wong, A. J. (2012) · Oncogene · doi:10.1038/onc.2012.280 · Cited by 143
Benner, S. E., Wahl, G. M., & Hoff, D. D. V. (1991) · Anti-Cancer Drugs · doi:10.1097/00001813-199102000-00002 · Cited by 139
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Brandes, A. A., Franceschi, E., Tosoni, A., Hegi, M. E., & Stupp, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1810 · Cited by 138
Haber, D. A., & SCHIMKE, R. T. (1981) · Cell · doi:10.1016/0092-8674(81)90204-x · Cited by 136
Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma
Nishikawa, R., Sugiyama, T., Narita, Y., Furnari, F. B., Cavenee, W. K., & Matsutani, M. (2004) · Brain Tumor Pathology · doi:10.1007/bf02484510 · Cited by 126
Self-citationTumor antigens in astrocytic gliomas
Kurpad, S. N., Zhao., X. ‐., Wikstrand, C. J., Batra, S. K., McLendon, R. E., & Bigner, D. D. (1995) · Glia · doi:10.1002/glia.440150306 · Cited by 113
Sun, J., Masterman-Smith, M. D., Graham, N. A., Jiao, J., Mottahedeh, J., Laks, D. R., Ohashi, M., DeJesus, J., Kamei, K., Lee, K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0076 · Cited by 111
Self-citationSanborn, Z., Salama, S. R., Grifford, M., Brennan, C., Mikkelsen, T., Jhanwar, S. C., Katzman, S. J., Chin, L., & Haussler, D. H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0186 · Cited by 105
Loss and Stabilization of Amplified Dihydrofolate Reductase Genes in Mouse Sarcoma S-180 Cell Lines
Kaufman, R. J., Brown, P. C., & SCHIMKE, R. T. (1981) · Molecular and Cellular Biology · doi:10.1128/mcb.1.12.1084 · Cited by 96
Jeuken, J. W. M., Sijben, A. E. J., Alenda, C., Rijntjes, J., Dekkers, M. M. G., Boots‐Sprenger, S., McLendon, R. E., & Wesseling, P. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00320.x · Cited by 79
Shimizu, N. (2009) · Cytogenetic and Genome Research · doi:10.1159/000218135 · Cited by 68
Cited by
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationIntratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009
Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity
Turner, K. M., Deshpande, V., Beyter, D., Koga, T., Rusert, J., Lee, C., Li, B., Arden, K., Ren, B., Nathanson, D. A., et al. (2017) · Nature · doi:10.1038/nature21356 · Cited by 847
Self-citation
Metadata
- Authors
- Nathanson, D. A., Gini, B., Mottahedeh, J., Visnyei, K., Koga, T., Gomez, G., Eskin, A., Hwang, K., Wang, J., Masui, K., Paucar, A., Yang, H., Ohashi, M., Zhu, S., Wykosky, J., Reed, R., Nelson, S. F., Cloughesy, T. F., James, C. D., Rao, P. N., Kornblum, H. I., Heath, J. R., Cavenee, W. K., Furnari, F. B., & Mischel, P. S.
- Venue
- Science
- Published
- 2014-01-03
- Volume
- 343
- Issue
- 6166
- Pages
- 72-76
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1987681742
- Cited by
- 695
- References
- 33
- FWCI
- 23.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.